|
|
|
08.05.25 - 11:57
|
Bulletin from Sobi′s Annual General Meeting (AGM) (PR Newswire)
|
|
|
STOCKHOLM, May 8, 2025 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 8 May 2025. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption of the profit and loss statements and balance sheet and......
|
|
|
08.05.25 - 11:51
|
Bulletin from Sobi′s Annual General Meeting (AGM) (PR Newswire)
|
|
|
STOCKHOLM, May 8, 2025 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 8 May 2025. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption of the profit and loss statements and balance sheet and......
|
|
|
|
|
29.04.25 - 08:15
|
Sobi publishes Q1 2025 report: Portfolio continues to deliver (PR Newswire)
|
|
|
STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025 First Quarter 2025 Total revenue increased 3 per cent, 3 per cent at constant exchange rates, (CER)1, to SEK 6,465 M (6,256) Haematology revenue......
|
|
|
29.04.25 - 08:12
|
Sobi publishes Q1 2025 report: Portfolio continues to deliver (PR Newswire)
|
|
|
STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025 First Quarter 2025 Total revenue increased 3 per cent, 3 per cent at constant exchange rates, (CER)1, to SEK 6,465 M (6,256) Haematology revenue......
|
|
|
|
|
31.03.25 - 15:06
|
Sobi publishes Annual and sustainability report for 2024 (PR Newswire)
|
|
|
STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform......
|
|
|
31.03.25 - 11:01
|
Sobi publishes Annual and sustainability report for 2024 (Cision)
|
|
|
Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases.
Sobi has a strong focus on building a sustainable business and ensuring that everyone eligible within its therapeutic areas has access to approved medicines.
The report includes the audited Annual report and the Sustainability report, which is Sobi's statutory sustainability report in accordance with the...
|
|
|
|
|
10.01.25 - 18:48
|
Sobi′s full year 2024 revenue higher than previous estimate (PR Newswire)
|
|
|
STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant......
|
|
|
10.01.25 - 18:42
|
Sobi′s full year 2024 revenue higher than previous estimate (PR Newswire)
|
|
|
STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant......
|
|
|
12.12.24 - 14:25
|
SOBI Announces FDA Acceptance Of New Drug Application For Avatrombopag (Reuters EN)
|
|
|
BRIEF-SOBI Announces FDA Acceptance Of New Drug Application For Avatrombopag Dec 12 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AVATROMBOPAG (DOPTELET®) FOR THE TREATMENT OF PEDIATRIC IMMUNE THROMBOCYTOPENIA SWEDISH ORPHAN BIOVITRUM AB (PUBL) - FDA SETS PDUFA TARGET ACTION DAT...
|
|
|
11.12.24 - 09:51
|
David Meek Elected Chair Of Board Of SOBI (Reuters EN)
|
|
|
BRIEF-David Meek Elected Chair Of Board Of SOBI Dec 11 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : DAVID MEEK WAS ELECTED AS NEW MEMBER OF BOARD OF DIRECTORS AND CHAIR OF BOARD OF DIRECTORS UNTIL END OF AGM 2025 Source text: ID:nWkrbkn6ZK Further company coverage: SOBIV.ST (Gdansk Newsroom)...
|
|
|
11.12.24 - 09:51
|
Bulletin from Sobi′s Extraordinary General Meeting (EGM) (PR Newswire)
|
|
|
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors......
|
|
|
11.12.24 - 09:45
|
Bulletin from Sobi′s Extraordinary General Meeting (EGM) (PR Newswire)
|
|
|
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors......
|
|
|
|
|
|
|
|
|
|
|
04.11.24 - 21:01
|
David Meek is proposed as new Chair of the Board of Directors of Sobi (Cision)
|
|
|
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.
David Meek currently serves as a member of the Board of Directors of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences. He also has previous experience from board work in listed pharmaceutical companies and US and European trade associations. David Meek has extensive experience...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
